Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Keisuke Aoe"'
Autor:
Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of cytotoxic T-lymphocyt
Externí odkaz:
https://doaj.org/article/6106be09c3614df6bee23c1408cd0096
Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
Autor:
Yasushi Goto, MD, PhD, Kodai Kawamura, MD, PhD, Tatsuro Fukuhara, MD, PhD, Yukiko Namba, MD, PhD, Keisuke Aoe, MD, PhD, Takehito Shukuya, MD, PhD, Takeshi Tsuda, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD
Publikováno v:
Current Therapeutic Research, Vol 99, Iss , Pp 100712- (2023)
ABSTRACT: Background: First-line immune checkpoint inhibitor (ICI) monotherapy for advanced non–small cell lung cancer (NSCLC) was introduced in Japan in February 2017. Limited information is available since that time regarding health care resource
Externí odkaz:
https://doaj.org/article/56826401c91e4ca1b5e8511e8fa71b5f
Autor:
Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Abstract Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or pr
Externí odkaz:
https://doaj.org/article/9fdb0934bf3d40bbb7a19d2b98a77955
Autor:
Nobukazu Fujimoto, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, Daijiro Harada
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/af8197ea96ff4fda8b8b228a37b81135
Autor:
Kazuhiko Nakagawa, MD, PhD, Takashi Kijima, MD, PhD, Morihito Okada, MD, PhD, Masahiro Morise, MD, PhD, Motoyasu Kato, MD, PhD, Katsuya Hirano, MD, Nobukazu Fujimoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Hiroshi Yokouchi, MD, PhD, Yuichiro Ohe, MD, PhD, Toyoaki Hida, MD, PhD, Keisuke Aoe, MD, PhD, Takumi Kishimoto, MD, PhD, Masato Hirokawa, MSc, Hironori Matsuki, MEng, Yutaro Kaneko, BSc, Taketo Yamada, MD, PhD, Chikao Morimoto, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100178- (2021)
Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesoth
Externí odkaz:
https://doaj.org/article/e0dd33bf32bd4e94a6baf9946819d8b9
Autor:
Yasuko Nagamatsu, Isao Oze, Keisuke Aoe, Katsuyuki Hotta, Katsuya Kato, Junko Nakagawa, Keiko Hara, Takumi Kishimoto, Nobukazu Fujimoto
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Malignant pleural mesothelioma (MPM) is a fatal and rare disease that is caused by the inhalation of asbestos. Treatment and care requests made by MPM patients to their physicians were collected and analyzed. Methods This cross-se
Externí odkaz:
https://doaj.org/article/18086f2c3c0b4f53b2196759ac5e814b
Autor:
Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100135- (2021)
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-liga
Externí odkaz:
https://doaj.org/article/6daaa024a9364fefa2c9b2eb6842a85c
Autor:
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Based on the results of the PACIFIC study, chemoradiotherapy followed by 1-year consolidation therapy with durvalumab was established as the standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC). Howeve
Externí odkaz:
https://doaj.org/article/96f6f9e07bb84541842c0f47686bf218
Autor:
Hiroshi Tanaka, Hiroyuki Suzuki, Junichi Shimizu, Daichi Fujimoto, Toshiyuki Kozuki, Osamu Hataji, Kyoichi Okishio, Ryo Morita, Haruhiro Saito, Hiroshi Sakai, Young Hak Kim, Makiko Yomota, Makoto Nishio, Keisuke Aoe, Osamu Kanai, Toru Kumagai, Kayoko Kibata, Hiroaki Tsukamoto, Satoshi Oizumi, Keiko Mizuno, Takeshi Masuda, Takashi Haku, Isamu Okamoto, Hirotoshi Hoshiyama, Nobumichi Yada, Yuichiro Ohe
Publikováno v:
ESMO Open, Vol 5, Iss 4 (2020)
Objectives We conducted a subanalysis of data from the multicentre, retrospective observational Nivolumab Japan Real World (CA209-9CR) study to evaluate nivolumab effectiveness and safety in elderly patients (aged ≥75 years) with advanced/metastati
Externí odkaz:
https://doaj.org/article/617a3f41e94246f9ad21a29cfa169c6e
Autor:
Yasuko Nagamatsu, Isao Oze, Keisuke Aoe, Katsuyuki Hotta, Katsuya Kato, Junko Nakagawa, Keiko Hara, Takumi Kishimoto, Nobukazu Fujimoto
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Previous studies have indicated that people with malignant pleural mesothelioma (MPM) have a poor quality of life (QOL); however, information about the QOL of people with MPM in Japan is anecdotal. The aims of this study were to i
Externí odkaz:
https://doaj.org/article/7889310e7bc84bb2b505a6027015fec2